New Discovered Adipokines Associated with the Pathogenesis of Obesity and Type 2 Diabetes

References

• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556. doi:10.1210/jc.2004-0395
   PubMed Web of Science ®Google Scholar
• Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45(1 Suppl):277–282.
   Web of Science ®Google Scholar
• Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405–408.
   Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
   PubMed Web of Science ®Google Scholar
• Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochemistry. 1993;217(1):13–19.
   Google Scholar
• Miyamae T, Marinov AD, Sowders D, et al. Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol. 2006;177(7):4758–4762.
   Web of Science ®Google Scholar
• Fan N, Sun H, Wang Y, et al. Follistatin-like 1: a potential mediator of inflammation in obesity. Mediators Inflamm. 2013;2013:752519.
   PubMed Web of Science ®Google Scholar
• Fang D, Shi X, Jia X, et al. Ups and downs: the PPARγ/p-PPARγ seesaw of follistatin-like 1 and integrin receptor signaling in adipogenesis. Mol Metab. 2022;55:101400.
   Web of Science ®Google Scholar
• Xu X, Zhang T, Mokou M, et al. Follistatin-like 1 as a Novel Adipomyokine Related to Insulin Resistance and Physical Activity. J Clin Endocrinol Metab. 2020;105(12):87.
   Web of Science ®Google Scholar
• Kon M, Tanimura Y, Yoshizato H. Effects of acute endurance exercise on follistatin-like 1 and apelin in the circulation and metabolic organs in rats. Arch Physiol Biochem. 2020;1:1–5.
   Google Scholar
• Horak M, Kuruczova D, Zlamal F, Tomandl J, Bienertova-Vasku J. Follistatin-Like 1 Is Downregulated in Morbidly and Super Obese Central-European Population. Dis Markers. 2018;2018:4140815.
   Web of Science ®Google Scholar
• Kon M, Ebi Y, Nakagaki K. Effects of acute sprint interval exercise on follistatin-like 1 and apelin secretions. Arch Physiol Biochem. 2021;127(3):223–227.
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res. 2007;13(14):4042–4045.
   PubMed Web of Science ®Google Scholar
• Yeger H, Perbal B. The CCN family of genes: a perspective on CCN biology and therapeutic potential. J Cell Commun Signal. 2007;1(3–4):159–164.
   PubMed Web of Science ®Google Scholar
• Murahovschi V, Pivovarova O, Ilkavets I, et al. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes. 2015;64(3):856–866.
   PubMed Web of Science ®Google Scholar
• Jung TW, Kang C, Goh J, et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol. 2018;233(8):6077–6087.
   Web of Science ®Google Scholar
• Hörbelt T, Tacke C, Markova M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9):2054–2065.
   Web of Science ®Google Scholar
• Fernandez-Ruiz R, García-Alamán A, Esteban Y, et al. Wisp1 is a circulating factor that stimulates proliferation of adult mouse and human beta cells. Nat Commun. 2020;11(1):5982.
   Web of Science ®Google Scholar
• Klimontov VV, Bulumbaeva DM, Fazullina ON, et al. Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal. 2020;14(1):101–109.
   Web of Science ®Google Scholar
• Tacke C, Aleksandrova K, Rehfeldt M, et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal. 2018;12(3):539–548.
   Web of Science ®Google Scholar
• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016;165(3):566–579.
   PubMed Web of Science ®Google Scholar
• Li E, Shan H, Chen L, et al. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019;30(2):319–328.e318.
   PubMed Web of Science ®Google Scholar
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444–1453.
   PubMed Web of Science ®Google Scholar
• Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96–104.
   PubMed Web of Science ®Google Scholar
• Wang R, Hu W. Asprosin promotes β-cell apoptosis by inhibiting the autophagy of β-cell via AMPK-mTOR pathway. J Cell Physiol. 2021;236(1):215–221.
   Web of Science ®Google Scholar
• Hekim MG, Kelestemur MM, Bulmus FG, et al. Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch Physiol Biochem. 2021;1–7.
   Web of Science ®Google Scholar
• Mishra I, Duerrschmid C, Ku Z, et al. Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. eLife. 2021;10.
   Web of Science ®Google Scholar
• Du C, Wang C, Guan X, et al. Asprosin is associated with anorexia and body fat mass in cancer patients. Supportive Care Cancer. 2021;29(3):1369–1375.
   Web of Science ®Google Scholar
• Ugur K, Aydin S. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. Int J Endocrinol. 2019;2019:2521096.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Lin T-A, Liu K-H, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int j Obesity. 2019;43(5):1019–1025.
   Web of Science ®Google Scholar
• Naiemian S, Naeemipour M, Zarei M, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:65.
   Web of Science ®Google Scholar
• Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–188.
   PubMed Web of Science ®Google Scholar
• Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm. 2018;2018:9471583.
   PubMed Web of Science ®Google Scholar
• Zhong L, Long Y, Wang S, et al. Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study. Placenta. 2020;93:17–22.
   Web of Science ®Google Scholar
• Zhang X, Jiang H, Ma X, Wu H. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2020;11(2):349–355.
   PubMed Web of Science ®Google Scholar
• Corica D, Pepe G, Aversa T, et al. Meal-Related Asprosin Serum Levels Are Affected by Insulin Resistance and Impaired Fasting Glucose in Children With Obesity. Front Endocrinol (Lausanne). 2021;12:805700.
   Web of Science ®Google Scholar
• Gkouskou KG, Georgiopoulos G, Vlastos I, et al. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. Int j Obesity. 2022;46(1):162–168.
   Web of Science ®Google Scholar
• Kantorowicz M, Szymura J, Szygula Z, Kusmierczyk J, Maciejczyk M, Wiecek M. Nordic Walking at Maximal Fat Oxidation Intensity Decreases Circulating Asprosin and Visceral Obesity in Women With Metabolic Disorders. Front Physiol. 2021;12:726783.
   PubMed Web of Science ®Google Scholar
• Wiecek M, Szymura J, Maciejczyk M, Kantorowicz M, Szygula Z. Acute Anaerobic Exercise Affects the Secretion of Asprosin, Irisin, and Other Cytokines - A Comparison Between Sexes. Front Physiol. 2018;9:1782.
   PubMed Web of Science ®Google Scholar
• Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2021;72(1):37–43.
   Web of Science ®Google Scholar
• Jiang A, Feng Z, Yuan L, Zhang Y, Li Q, She Y. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus. Diabetol Metab Syndr. 2021;13(1):34.
   Web of Science ®Google Scholar
• Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329(5990):454–457.
   PubMed Web of Science ®Google Scholar
• Rulifson IC, Majeti JZ, Xiong Y, et al. Inhibition of secreted frizzled-related protein 5 improves glucose metabolism. Am J Physiol Endocrinol Metab. 2014;307(12):E1144–1152.
   Web of Science ®Google Scholar
• Rebuffat SA, Oliveira JM, Altirriba J, et al. Downregulation of Sfrp5 promotes beta cell proliferation during obesity in the rat. Diabetologia. 2013;56(11):2446–2455.
   Web of Science ®Google Scholar
• Rydzewska M, Nikołajuk A, Matulewicz N, Stefanowicz M, Karczewska-Kupczewska M. Serum secreted frizzled-related protein 5 in relation to insulin sensitivity and its regulation by insulin and free fatty acids. Endocrine. 2021;74(2):300–307.
   Web of Science ®Google Scholar
• Hu W, Li L, Yang M, et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2013;98(1):290–298.
   PubMed Web of Science ®Google Scholar
• Hu Z, Deng H, Qu H. Plasma SFRP5 levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance. Diabetes Res Clin Pract. 2013;99(3):391–395.
   PubMed Web of Science ®Google Scholar
• Carstensen-Kirberg M, Kannenberg JM, Huth C, et al. Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study. Cardiovasc Diabetol. 2017;16(1):109.
   PubMed Web of Science ®Google Scholar
• He X, Ma H. Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation. Diabetes Metabolic Syndrome Obesity. 2020;13:1243–1250.
   PubMed Web of Science ®Google Scholar
• Xu Q, Wang H, Li Y, et al. Plasma Sfrp5 levels correlate with determinants of the metabolic syndrome in Chinese adults. Diabetes Metab Res Rev. 2017;33(6):875.
   Web of Science ®Google Scholar
• Lu Y-C, Wang C-P, Hsu -C-C, et al. Circulating secreted frizzled-related protein 5 (Sfrp5) and wingless-type MMTV integration site family member 5a (Wnt5a) levels in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2013;29(7):551–556.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ran Y, Kong L, et al. Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. J Ovarian Res. 2021;14(1):97.
   Web of Science ®Google Scholar
• Li Z-Y, Zheng S-L, Wang P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014;20(4):344–354.
   PubMed Web of Science ®Google Scholar
• Rao RR, Long JZ, White JP, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279–1291.
   PubMed Web of Science ®Google Scholar
• Lee JO, Byun WS, Kang MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2. FEBS J. 2020;287(10):2087–2104.
   PubMed Web of Science ®Google Scholar
• Hu W, Wang R, Sun B. Meteorin-Like Ameliorates β Cell Function by Inhibiting β Cell Apoptosis of and Promoting β Cell Proliferation via Activating the WNT/β-Catenin Pathway. Front Pharmacol. 2021;12:627147.
   Web of Science ®Google Scholar
• Qi Q, Hu W-J, Zheng S-L, et al. Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride. Acta Pharmacol Sin. 2020;41(12):1568–1575.
   Web of Science ®Google Scholar
• Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018;13(9):e0204180.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang YE, Kim JM, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract. 2018;135:7–10.
   PubMed Web of Science ®Google Scholar
• El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57–63.
   Web of Science ®Google Scholar
• Fadaei R, Dadmanesh M, Moradi N, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules. Arch Physiol Biochem. 2020;126(4):335–340.
   PubMed Web of Science ®Google Scholar
• Chung HS, Hwang SY, Choi JH, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:100–107.
   PubMed Web of Science ®Google Scholar
• AlKhairi I, Cherian P, Abu-Farha M, et al. Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin. Cells. 2019;8(10):325.
   Web of Science ®Google Scholar
• Cherian P, Al-Khairi I, Jamal M, et al. Association Between Factors Involved in Bone Remodeling (Osteoactivin and OPG) With Plasma Levels of Irisin and Meteorin-Like Protein in People With T2D and Obesity. Front Endocrinol (Lausanne). 2021;12:752892.
   Web of Science ®Google Scholar
• Wu Q, Dan Y-L, He Y-S, et al. Circulating Meteorin-like Levels in Patients with Type 2 Diabetes Mellitus: a Meta-Analysis. Curr Pharm Des. 2020;26(44):5732–5738.
   Web of Science ®Google Scholar
• Ferns GA, Fekri K, Abadi MSS, Dehkordi MB, Arjmand M-H. A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease. Arch Physiol Biochem. 2021;1–7.
   Web of Science ®Google Scholar
• Schmid A, Karrasch T, Schäffler A. Meteorin-Like Protein (Metrnl) in Obesity, during Weight Loss and in Adipocyte Differentiation. J Clin Med. 2021;10(19):87.
   Web of Science ®Google Scholar
• Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int j Obesity. 2018;42(4):919–922.
   Web of Science ®Google Scholar
• Bonfante ILP, Monfort-Pires M, Duft RG, et al. Combined training increases thermogenic fat activity in patients with overweight and type 2 diabetes. Int j Obesity. 2022;1:56.
   Google Scholar
• Harari D, Tzahar E, Romano J, et al. Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene. 1999;18(17):2681–2689.
   PubMed Web of Science ®Google Scholar
• Wang G-X, Zhao X-Y, Meng Z-X, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis. Nat Med. 2014;20(12):1436–1443.
   Web of Science ®Google Scholar
• Zeng F, Wang Y, Kloepfer LA, Wang S, Harris RC. ErbB4 deletion predisposes to development of metabolic syndrome in mice. Am J Physiol Endocrinol Metab. 2018;315(4):E583–E593.
   Web of Science ®Google Scholar
• Ma Y, Gao M, Liu D. Preventing High Fat Diet-induced Obesity and Improving Insulin Sensitivity through Neuregulin 4 Gene Transfer. Sci Rep. 2016;6:26242.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang G-X, Ma SL, et al. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders. Mol Metab. 2017;6(8):863–872.
   Web of Science ®Google Scholar
• South JCM, Blackburn E, Brown IR, Gullick WJ. The neuregulin system of ligands and their receptors in rat islets of Langerhans. Endocrinology. 2013;154(7):2385–2392.
   Web of Science ®Google Scholar
• Yang F, Zhou N, Zhu X, Min C, Zhou W, Li X. n-3 PUFAs protect against adiposity and fatty liver by promoting browning in postnatally overfed male rats: a role for NRG4. J Nutr Biochem. 2021;93:108628.
   Web of Science ®Google Scholar
• Zhang L, Bai M, Tang H, et al. Role of hepatic neuregulin 4 in the regulation of gluconeogenesis in mice. Life Sci. 2019;217:185–192.
   PubMed Web of Science ®Google Scholar
• Guo D, Liu J, Zhang P, et al. Adiposity Measurements and Metabolic Syndrome Are Linked Through Circulating Neuregulin 4 and Adipsin Levels in Obese Adults. Front Physiol. 2021;12:667330.
   Web of Science ®Google Scholar
• Zhang L, Fu Y, Zhou N, Cheng X, Chen C. Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study. Endocrine. 2017;57(3):535–538.
   Web of Science ®Google Scholar
• Cai C, Lin M, Xu Y, Li X, Yang S, Zhang H. Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study. BMC Med. 2016;14(1):165.
   Web of Science ®Google Scholar
• Yan P, Xu Y, Wan Q, et al. Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus. Dis Markers. 2018;2018:6974191.
   Web of Science ®Google Scholar
• Kang YE, Kim JM, Choung S, et al. Comparison of serum Neuregulin 4 (Nrg4) levels in adults with newly diagnosed type 2 diabetes mellitus and controls without diabetes. Diabetes Res Clin Pract. 2016;117:1–3.
   PubMed Web of Science ®Google Scholar
• Chen -L-L, Peng -M-M, Zhang J-Y, et al. Elevated circulating Neuregulin4 level in patients with diabetes. Diabetes Metab Res Rev. 2017;33(4):87.
   Web of Science ®Google Scholar
• Kocak MZ, Aktas G, Erkus E, et al. Neuregulin-4 is associated with plasma glucose and increased risk of type 2 diabetes mellitus. Swiss Med Wkly. 2019;149:w20139.
   PubMed Web of Science ®Google Scholar
• Żebrowska A, Hall B, Stolecka-Warzecha A, Stanula A, Sadowska-Krępa E. The Effect of Omega-3 Fatty Acid Supplementation on Serum Adipocytokines, Lipid Profile and Biochemical Markers of Inflammation in Recreational Runners. Nutrients. 2021;13(2):87.
   Web of Science ®Google Scholar
• Saeidi A, Shishvan SR, Soltani M, et al. Differential Effects of Exercise Programs on Neuregulin 4, Body Composition and Cardiometabolic Risk Factors in Men With Obesity. Front Physiol. 2021;12:797574.
   Web of Science ®Google Scholar
• Elbarbary NS, Ismail EAR, Ghallab MA. Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: a randomized controlled trial. Diabetes Res Clin Pract. 2022;186:109857.
   Web of Science ®Google Scholar
• Tang YT, Emtage P, Funk WD, et al. TAFA: a novel secreted family with conserved cysteine residues and restricted expression in the brain. Genomics. 2004;83(4):727–734.
   Web of Science ®Google Scholar
• Wang Y, Chen D, Zhang Y. Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury through Sphingosine-1-Phosphate Receptor 2. Circulation. 2018;138(1):48–63.
   PubMed Web of Science ®Google Scholar
• Yari FA, Shabani P, Karami S, Sarmadi N, Poustchi H, Bandegi AR. Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease. BMC Endocr Disord. 2021;21(1):153.
   Web of Science ®Google Scholar
• Xie K, Liu L, Yin C, et al. Follistatin-like 1 and family with sequence similarity to 19 member A5 levels are decreased in obese children and associated with glucose metabolism. Ann Nutr Metab. 2022.
   Web of Science ®Google Scholar
• Lee YB, Hwang HJ, Kim JA, et al. Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes. Diab Vasc Dis Res. 2019;16(6):530–538.
   PubMed Web of Science ®Google Scholar
• Mahlangu T, Dludla PV, Nyambuya TM, et al. A systematic review on the functional role of Th1/Th2 cytokines in type 2 diabetes and related metabolic complications. Cytokine. 2020;126:154892.
   PubMed Web of Science ®Google Scholar